Table 2 Coagulation status
Variable | Total | No Radiographic progression | Radiographic progression | p value |
|---|---|---|---|---|
Sample (N) | 340 | 321 | 19 | – |
Anticoagulation/ Antiplatelet use | 150 (44%) | 139 (43.3%) | 11 (58%) | 0.239 |
Anticoagulation | 51 (15%) | 46 (14.3%) | 5 (26.3%) | 0.18 |
Warfarin | 28 (54.9%) | 23 (50%) | 5 (100%) | 0.003 |
Xarelto | 10 (19.6%) | 10 (21.7%) | 0 | – |
Eliquis | 6 (11.8%) | 6 (13%) | 0 | – |
Pradaxa | 4 (7.8%) | 4 (8.7%) | 0 | – |
Others | 3 (5.9%) | 3 (6.5%) | 0 | – |
Antiplatelets | 128 (37.6%) | 118 (36.8%) | 10 (52.6%) | 0.165 |
Aspirin | 102 (79.7%) | 94 (79.7%) | 8 (80%) | 0.982 |
Plavix | 8 (6.3%) | 8 (6.8%) | 0 | – |
Aspirin/Plavix | 14 (10.9%) | 12 (10.2%) | 2 (20%) | 0.3428 |
Others | 4 (3.1%) | 4 (3.4%) | 0 | – |
Coagulation studies (at presentation) | ||||
INR | 1.15 ± 0.5 | 1.14 ± 0.5 | 1.32 ± 0.5 | 0.107 |
PTT | 29.7 ± 5.8 | 29.6 ± 5.7 | 31 ± 7.5 | 0.405 |
Platelet count (thousands) | 219.8 ± 68.1 | 221.1 ± 67.9 | 199.3 ± 70.9 | 0.175 |
TEG inhibition | ||||
AA (%) | 17.1 ± 33 | 16.9 ± 32.8 | 20.8 ± 38.6 | 0.741 |
ADP (%) | 17 ± 28.9 | 16.7 ± 28.5 | 21.3 ± 39.5 | 0.664 |
Medication reversed | 33 (22%) | 28 (20.1%) | 5 (45.5%) | 0.051 |